|
|
News Breaks
|
November 2, 2009
|
| 10:31 EDT |  | CXM |
| theflyonthewall.com: | Cardium Therapeutics plans to file 510k application for Excellagen | | Cardium Therapeutics announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate. ExcellagenXL is an advanced wound care management medical device, which is a customized collagen-based topical gel designed for use by physicians in patients with topical wounds, which include diabetic ulcers as well as pressure ulcers, venous ulcers, surgical and trauma wounds, second degree burns, and other types of wounds. The Company expects to submit its FDA 510(k) application for ExcellagenXL during the current quarter. :theflyonthewall.com |
|
|
News For CXM From The Last 14 Days Check below for free stories on CXM the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 09:13 EDT | | CXM |
| | 09:09 EDT |  | CXM |
| theflyonthewall.com: | Cardium Therapeutics files to sell 17.9M shares in a direct offering | | The investors have agreed to purchase the shares of common stock for a price of 28c per share with no warrant coverage. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., acted as the exclusive placement agent for the offering. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information